Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$146.45 USD
+2.32 (1.61%)
Updated Aug 8, 2024 12:06 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 181 - 200 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Eye of the Storm? 2Q20 Commercial Biotech Preview
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 7/3/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 6/26/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Biotechnology-Neurology Prescription Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Mechanistic Ponderings Following Announcement of Takeda Psychiatric Collaboration; PT to $131
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Let''s Make a Deal; NBIX Expands Into Neuropsych With Takeda
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Crinecerfont Continues to Shine in CAH; Reit Buy and $125 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Initiating at Outperform, $147 Target; Making The Move into Movement Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Biotechnology - Neurology Prescription Sales Tracker -- Week Ending 3/27/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker -- Week Ending 3/13/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 3/13/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker -- Week Ending 3/06/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
From Ingrezza to 2020 Pivotal Trial Development, Pipeline Lays Foundation for Growth.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Continued Ingrezza Momentum Complemented by Progress in PD and CAH Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Underlying Business Continues to Outperform as Pipeline and Cash Position Offer Multiple Sources of Upside Optionality
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Looking Past Ingrezza Seasonality, We See a Number of Fundamental Drivers of Value Ahead; Reit Buy and $102 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
The Positive CAH Interim Data Should Clear the Way for the Regulatory Talk; Reit Buy and $102 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A